This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Abbott, Karo Bio develop Type II diabetes drugs; ended
21 Oct 2004
Abbott Laboratories and Swedish pharmaceutical Karo Bio AB signed a three-year deal to develop Type II diabetes therapeutics. Abbott will use Karo Bio's nuclear receptor technology and potential drug candidates, and the partners will together handle research and preclinical development.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?